Citadel Advisors
SYRE icon

Citadel Advisors’s Spyre Therapeutics SYRE Stock Holding History

Citadel Advisors’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.15M Sell
103,100
-5,035
-5% -$367K ﹤0.01% 3704
2026
Q1 		$5.45M Buy
108,135
+44,231
+69% +$1.67M ﹤0.01% 4206
2025
Q4 		$2.09M Buy
+63,904
New +$1.67M ﹤0.01% 5818
2025
Q2 		– Sell
-130,884
Closed -$2.11M – 15014
2025
Q1 		$2.11M Sell
130,884
-948,423
-88% -$19.7M ﹤0.01% 5436
2024
Q4 		$25.1M Buy
1,079,307
+371,721
+53% +$10.9M ﹤0.01% 1919
2024
Q3 		$20.8M Hold
707,586
– – ﹤0.01% 2012
2024
Q2 		$16.6M Sell
707,586
-4
-0% -$135 ﹤0.01% 2189
2024
Q1 		$26.8M Buy
707,590
+130,879
+23% +$3.79M 0.01% 1778
2023
Q4 		$12.4M Buy
576,711
+479,658
+494% +$6.61M ﹤0.01% 2570
2023
Q3 		$1.19M Buy
+97,053
New +$1.28M ﹤0.01% 6215
2023
Q1 		– Sell
-619
Closed -$6.96K – 15500
2022
Q4 		$6.96K Sell
619
-1,812
-75% -$32.6K ﹤0.01% 13867
2022
Q3 		$32K Sell
2,431
-6,657
-73% -$82.2K ﹤0.01% 11872
2022
Q2 		$115K Buy
9,088
+6,151
+209% +$216K ﹤0.01% 11274
2022
Q1 		$169K Buy
+2,937
New +$247K ﹤0.01% 11716
2021
Q1 		– Sell
-1,349
Closed -$259K – 13699
2020
Q4 		$265K Sell
1,349
-552
-29% -$114K ﹤0.01% 9277
2020
Q3 		$337K Buy
1,901
+775
+69% +$143K ﹤0.01% 7937
2020
Q2 		$261K Buy
1,126
+178
+19% +$33.9K ﹤0.01% 8135
2020
Q1 		$110K Buy
948
+368
+63% +$62.6K ﹤0.01% 8568
2019
Q4 		$111K Buy
+580
New +$114K ﹤0.01% 8504
2019
Q3 		– Sell
-1,189
Closed -$203K – 9739
2019
Q2 		$203K Sell
1,189
-3,579
-75% -$619K ﹤0.01% 8169
2019
Q1 		$960K Buy
+4,768
New +$994K ﹤0.01% 5664
2016
Q3 		– Sell
-514
Closed -$62K – 7760
2016
Q2 		$62K Buy
+514
New +$98.5K ﹤0.01% 6356

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Citadel Advisors's SYRE Position: Q2 2026 in Review

Citadel Advisors reduced its Spyre Therapeutics (SYRE) stake by 4.7% in Q2 2026, selling an estimated $367K and leaving 103,100 shares worth $9.15M. The position accounts for ﹤0.01% of the portfolio, ranked #3704.

Citadel Advisors first reported a position in SYRE in Q2 2016 and has held it in 22 quarters since. The position peaked at $26.8M in Q1 2024. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Citadel Advisors held 103,100 shares of Spyre Therapeutics worth $9.15M as of Q2 2026.
  • Citadel Advisors sold 5,035 Spyre Therapeutics shares in Q2 2026, an estimated $367K.
  • Spyre Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #3704 holding.
  • Citadel Advisors first reported a position in Spyre Therapeutics in Q2 2016 and has held it in 22 quarters since.
  • Citadel Advisors's Spyre Therapeutics position peaked at $26.8M in Q1 2024.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.